Revenue: As of FY2025 Q3, the actual value is USD 590.05 K.EPS: As of FY2025 Q3, the actual value is USD -0.19.EBIT: As of FY2025 Q3, the actual value is USD -2.559 M.<h3>Segment Revenue</h3><ul><li>Revenues: For the three months ended September 30, 2025, revenues were $590,050, compared to $64,861 for the same period in 2024, representing an increase of 810%.</li><li>Revenues: For the nine months ended September 30, 2025, revenues were $600,308, compared to $83,560 for the same period in 2024, representing an increase of 618%.</li></ul><h3>Operational Metrics</h3><ul><li>Gross Profit: For the three months ended September 30, 2025, gross profit was $574,621, compared to $3,883 for the same period in 2024, representing an increase of 14698%.</li><li>Gross Profit: For the nine months ended September 30, 2025, gross profit was $575,294, compared to $3,180 for the same period in 2024, representing an increase of 17991%.</li><li>Operating Loss: For the three months ended September 30, 2025, operating loss was - $4,361,206, compared to - $3,497,791 for the same period in 2024.</li><li>Operating Loss: For the nine months ended September 30, 2025, operating loss was - $13,090,429, compared to - $10,486,453 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was - $8,204,389, compared to - $11,355,826 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided by financing activities was $8,251,985, compared to - $15,769,770 for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Interest Expense: For the three months ended September 30, 2025, interest expense was - $1,803,430, compared to - $217,433 for the same period in 2024.</li><li>Interest Expense: For the nine months ended September 30, 2025, interest expense was - $3,127,707, compared to - $320,897 for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to advance product candidates through clinical studies and toward commercialization, drive growth and profitability using dedicated sales and marketing resources, continue to grow its pipeline, and target strategic business development opportunities.</li><li>Non-Core Business: The company completed the sale of its subsidiaries, IPS, Softell, and Bonum Health, Inc., to Tollo in exchange for a $5,000,000 promissory note, as part of a broader strategic realignment designed to sharpen operational focus and unlock long-term value.</li></ul><h3>Priority</h3><ul><li>Strategic Realignment: The divestitures are aligned with the company’s commitment to streamline its core operations, optimize its portfolio, and accelerate growth in the Branded and Specialty Pharma markets.</li></ul>

Scienture | 10-Q: FY2025 Q3 Revenue: USD 590.05 K